433 related articles for article (PubMed ID: 36706634)
21. Anisomycin has a potential toxicity of promoting cuproptosis in human ovarian cancer stem cells by attenuating YY1/lipoic acid pathway activation.
Nie X; Chen H; Xiong Y; Chen J; Liu T
J Cancer; 2022; 13(14):3503-3514. PubMed ID: 36484005
[TBL] [Abstract][Full Text] [Related]
22. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
23. Copper Homeostasis Based on Cuproptosis-Related Signature Optimizes Molecular Subtyping and Treatment of Glioma.
Zhang S; Yu H; Sun S; Fan X; Bi W; Li S; Wang W; Fang Z; Chen X
Mol Neurobiol; 2023 Dec; ():. PubMed ID: 38151613
[TBL] [Abstract][Full Text] [Related]
24. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
[TBL] [Abstract][Full Text] [Related]
25. Lactylation of METTL16 promotes cuproptosis via m
Sun L; Zhang Y; Yang B; Sun S; Zhang P; Luo Z; Feng T; Cui Z; Zhu T; Li Y; Qiu Z; Fan G; Huang C
Nat Commun; 2023 Oct; 14(1):6523. PubMed ID: 37863889
[TBL] [Abstract][Full Text] [Related]
26. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
27. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
Gao J; Wu X; Huang S; Zhao Z; He W; Song M
Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
[TBL] [Abstract][Full Text] [Related]
28. Qiju Dihuang Pill protects the lens epithelial cells via alleviating cuproptosis in diabetic cataract.
Yang J; Gao Y; Mao H; Kuang X; Tian F
J Ethnopharmacol; 2024 Jun; 333():118444. PubMed ID: 38851473
[TBL] [Abstract][Full Text] [Related]
29. Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death.
Gao X; Zhao H; Liu J; Wang M; Dai Z; Hao W; Wang Y; Wang X; Zhang M; Liu P; Cheng H; Liu Z
Adv Sci (Weinh); 2024 Jun; ():e2401396. PubMed ID: 38859590
[TBL] [Abstract][Full Text] [Related]
30. miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis.
Liu S; Xiao Z; Ai F; Liu F; Chen X; Cao K; Ren W; Zhang X; Shu P; Zhang D
Biomed Pharmacother; 2017 Aug; 92():1119-1127. PubMed ID: 28622713
[TBL] [Abstract][Full Text] [Related]
31. Cope with copper: From molecular mechanisms of cuproptosis to copper-related kidney diseases.
Zou Y; Wu S; Xu X; Tan X; Yang S; Chen T; Zhang J; Li S; Li W; Wang F
Int Immunopharmacol; 2024 May; 133():112075. PubMed ID: 38663316
[TBL] [Abstract][Full Text] [Related]
32. A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy.
Shen W; Pei P; Zhang C; Li J; Han X; Liu T; Shi X; Su Z; Han G; Hu L; Yang K
ACS Nano; 2023 Dec; 17(23):23998-24011. PubMed ID: 37988029
[TBL] [Abstract][Full Text] [Related]
33. Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy.
Lu X; Chen X; Lin C; Yi Y; Zhao S; Zhu B; Deng W; Wang X; Xie Z; Rao S; Ni Z; You T; Li L; Huang Y; Xue X; Yu Y; Sun W; Shen X
Adv Sci (Weinh); 2024 May; 11(18):e2309984. PubMed ID: 38430531
[TBL] [Abstract][Full Text] [Related]
34. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression.
Zhao Q; Qi T
Front Oncol; 2023; 13():1117164. PubMed ID: 36925927
[TBL] [Abstract][Full Text] [Related]
35. FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis.
Chen G; Zhang J; Teng W; Luo Y; Ji X
Heliyon; 2023 Aug; 9(8):e18655. PubMed ID: 37554785
[TBL] [Abstract][Full Text] [Related]
36. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
[TBL] [Abstract][Full Text] [Related]
37. A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.
Zhu Z; Zhao Q; Song W; Weng J; Li S; Guo T; Zhu C; Xu Y
Front Immunol; 2022; 13():940774. PubMed ID: 36248908
[TBL] [Abstract][Full Text] [Related]
38. GSH exhaustion via inhibition of xCT-GSH-GPX4 pathway synergistically enhanced DSF/Cu-induced cuproptosis in myelodysplastic syndromes.
Li H; Li Y; Yu Y; Ren X; Yang C; Jin W; Li K; Zhou Y; Wu C; Shen Y; Hu W; Liu Y; Yu L; Tong X; Du J; Wang Y
Free Radic Biol Med; 2024 Jun; 222():130-148. PubMed ID: 38866192
[TBL] [Abstract][Full Text] [Related]
39. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
[TBL] [Abstract][Full Text] [Related]
40. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
